This chapter reviews the available evidence on screening for type 1, type 2, and gestational diabetes, as well as data on screening for impaired glucose tolerance. Screening for a disease should only be undertaken when well‐established principles are satisfied. Most importantly, treatment should be of proven efficacy, and the disease should have serious consequences and a prolonged asymptomatic phase. Ideally, a screening program should be tested in randomized controlled trials. For type 2 diabetes, there is now mounting evidence that targeted screening may be valuable in preventing the disease or reducing the likelihood of developing its complications. In the absence of any preventative therapy, screening for type 1 diabetes, however, cannot be justified outside clinical trials. Screening for gestational diabetes is widely practiced, but disagreement remains on diagnostic thresholds and screening strategies.